RxDoctor Payments DataLook up a doctor →

Stephanie Mehlis, MD

Dermatology · Skokie, ILNPI 1770634131

Payments from drug & device makers

$6,427,275in general payments, 2019–2025

Across 1,146 payments — averaging $5608.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.4M
  • UCB SA$1.2M
  • Pfizer$1.2M
  • E.r. Squibb & Sons, L.L.C.$494K
  • AbbVie$486K
  • Takeda Pharmaceuticals U.S.A., Inc.$474K
  • plus $1.1M from 21 others
$13,044in research payments, 2019–2025

Across 16 payments — averaging $815.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$6K
  • Pfizer$6K
  • F. Hoffmann-la Roche AG$659
  • AbbVie$148

What the payments were for

  • Consulting fees$36,32125%
  • Speaking & faculty fees$91,35263%
  • Travel & lodging$11,1758%
  • Food & beverage$5,5604%
  • Education$3580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,427,275 in reported general payments places this provider in the 95th percentile of 606 dermatology providers in Illinois.

See all dermatology providers in Illinois

Medicare billing

Part B allowed, 2024
$100,011
Medicare patients
651
Services billed
1,915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept17$429,947
StelaraUstekinumab19$413,252
Cosentyx Sensoready (2 Pens)Secukinumab44$390,746
Skyrizi PenRisankizumab-Rzaa18$372,049
Taltz AutoinjectorIxekizumab11$106,466
Humira(Cf)Adalimumab13$90,543
Dupixent SyringeDupilumab14$54,614
Calcipotriene26$7,261
Pimecrolimus16$4,904
Clobetasol Propionate77$3,803
Tacrolimus23$2,692
Halobetasol Propionate15$2,196
Ketoconazole127$1,852
Triamcinolone Acetonide160$1,584
Metronidazole30$1,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$64,695$413,25219 claims
AbbVieHumira(Cf)$486,243$90,54313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 606 dermatology providers in Illinois.

Other dermatology in Skokie

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →